Latest News
Chronosphere pits AI against Datadog, touts 85% cost cut, 10× Black Friday load Experts advise locating new US data centers outside water‑stressed California ASEAN's USD 300B digital economy draws USD 2.3B into 680+ AI startups CNN app introduces new ‘Shorts’ tab for bite‑size news videos Qodo’s Git‑integrated, human‑in‑the‑loop model eases AI code overload Tim Berners‑Lee says AI won’t destroy the web, despite Pichai’s comment Baseten takes on hyperscalers with AI platform that lets users own model weights AI Master's Programs Jump 167% to 310 Across 304 U.S. Colleges Chronosphere pits AI against Datadog, touts 85% cost cut, 10× Black Friday load Experts advise locating new US data centers outside water‑stressed California ASEAN's USD 300B digital economy draws USD 2.3B into 680+ AI startups CNN app introduces new ‘Shorts’ tab for bite‑size news videos Qodo’s Git‑integrated, human‑in‑the‑loop model eases AI code overload Tim Berners‑Lee says AI won’t destroy the web, despite Pichai’s comment Baseten takes on hyperscalers with AI platform that lets users own model weights AI Master's Programs Jump 167% to 310 Across 304 U.S. Colleges
Content generation system is offline for maintenance. Manual curation in progress.
Research & Benchmarks

Pharma Cautious as AI Promises Faster Drug Discovery and Smarter Trials

By
• 2 min read

The industry’s buzz around artificial intelligence has turned boardrooms into testing grounds. Executives are weighing glossy pilot studies against the gritty reality of bringing a molecule from computer to clinic. While startups parade algorithms that can sift through billions of compounds in days, legacy firms still wrestle with legacy data, siloed teams and the cost of re‑tooling pipelines.

Add to that a wave of regulatory paperwork—recent FDA guidance spells out how machine‑learning models must be documented, validated and monitored once they touch patients. That mix of optimism and caution is why the next line matters.

Pharmaceutical companies often find themselves at a crossroads with every new technology--eager to lead, yet cautious about its reliability. AI promises faster drug discovery, smarter clinical trials and more personalised patient care. But as regulators like the FDA roll out detailed guidance on AI and machine-learning-based medical devices, the industry faces a sharper question: how to innovate at speed without tripping over compliance? According to Manish Mittal, managing principal and India business head at Axtria, the answer lies in embedding compliance into the DNA of AI programmes rather than treating it as an afterthought.

Related Topics: #AI #machine‑learning #drug discovery #clinical trials #FDA #Axtria #Manish Mittal #regulatory guidance

Will AI deliver on its promises? Pharma executives are watching closely, yet they're still wary. The allure of quicker drug discovery and smarter clinical trials sits beside a growing pile of regulatory guidance from the FDA, which now details how machine‑learning‑based medical devices must be vetted.

Manish Mittal notes that companies often stand at a crossroads, eager to lead but cautious about reliability. This tension forces a delicate balance: push innovation fast enough to stay competitive, but not so fast that compliance slips. Some pilots have shown early gains, but the broader impact on timelines and patient outcomes is still unclear.

Regulators are tightening rules, and firms must adapt their R&D pipelines accordingly. Without clear evidence that AI can consistently meet safety standards, investment decisions will likely stay measured. In short, the sector’s enthusiasm is tempered by practical concerns over validation, oversight, and the real‑world performance of these new tools.

Further Reading

Related Articles

Common Questions Answered

How does AI promise to accelerate drug discovery according to the article?

The article states that AI algorithms can sift through billions of compounds in days, dramatically shortening the time needed to identify promising drug candidates. This speed advantage could move molecules from computer modeling to clinical testing far faster than traditional methods.

What regulatory challenges does the FDA guidance introduce for machine‑learning‑based medical devices?

According to the piece, the FDA's detailed guidance outlines strict vetting procedures for AI and machine‑learning models used in medical devices, emphasizing reliability and compliance. Companies must navigate this paperwork while trying to innovate, creating a tension between rapid development and regulatory adherence.

Why are legacy pharmaceutical firms hesitant to adopt AI despite its potential benefits?

Legacy firms struggle with entrenched data silos, outdated pipelines, and the high cost of re‑tooling, which makes AI integration risky. The article highlights that these operational hurdles, combined with uncertainty around regulatory compliance, temper their enthusiasm for AI adoption.

What does Manish Mittal identify as the main dilemma for pharma executives regarding AI?

Manish Mittal notes that executives are at a crossroads, eager to lead with AI-driven innovation but cautious about the technology's reliability and regulatory scrutiny. This dilemma forces them to balance the lure of faster drug discovery and smarter trials against the need for compliance and proven performance.

How might AI improve the design of clinical trials as mentioned in the article?

The article suggests AI can create smarter clinical trial designs by analyzing patient data to personalize treatment arms and predict outcomes. This capability could reduce trial durations, lower costs, and increase the likelihood of successful drug approvals.